Smart polymers for advanced applications: a mechanical perspective review

Responsive materials, as well as active structural systems, are nowadays widely used to develop unprecedented smart devices, sensors or actuators; their functionalities come from the ability of responding to environmental stimuli with a detectable reaction. Depending on the responsive material under study, the triggering stimuli can have a different nature, ranging from physical (temperature, light, electric or magnetic field, mechanical stress, ...), chemical (pH, ligands, …), or biological (enzymes, …) type. Such a responsiveness can be obtained by properly designing the meso- or macroscopic arrangement of the constitutive elements, as occurs in metamaterials, or can be obtained by using responsive materials per se, whose responsiveness comes from the chemistry underneath their microstructure. In fact, when the responsiveness at the molecular level is properly organized, the nanoscale response can be collectively detected at the macroscale, leading to a responsive material. In the present paper, we review the huge world of responsive polymers, by outlining the main features, characteristics and responsive mechanisms of smart polymers and by providing a mechanical modeling perspective, both at the molecular as well as at the continuum scale level. We aim at providing a comprehensive overview of the main features and modeling aspects of the most diffused smart polymers. The quantitative mechanical description of active materials plays a key role in their development and use, enabling the design of advanced devices as well as to engineer the materials’ microstructure according to the desired functionality

The mechanical response of fire ant rafts

Fire ants (Solenopsis invicta) cohesively aggregate via the formation of voluntary ant-to-ant attachments when under confinement or exposed to water. Once formed, these aggregations act as viscoelastic solids due to dynamic bond exchange between neighboring ants as demonstrated by rate-dependent mechanical response of 3D aggregations, confined in rheometers. We here investigate the mechanical response of 2D, planar ant rafts roughly as they form in nature. Specifically, we load rafts under uniaxial tension to failure, as well as to 50% strain for two cycles with various recovery times between. We do so while measuring raft reaction force (to estimate network-scale stress), as well as the networks' instantaneous velocity fields and topological damage responses to elucidate the ant-scale origins of global mechanics. The rafts display brittle-like behavior even at slow strain rates (relative to the unloaded bond detachment rate) for which Transient Network Theory predicts steady-state creep. This provides evidence that loaded ant-to-ant bonds undergo mechanosensitive bond stabilization or act as \say{catch bonds}. This is further supported by the coalescence of voids that nucleate due to biaxial stress conditions and merge due to bond dissociation. The characteristic timescales of void coalescence due to chain dissociation provide evidence that the local detachment of stretched bonds is predominantly strain- (as opposed to bond lifetime-) dependent, even at slow strain rates, implying that bond detachment rates diminish significantly under stretch. Significantly, when the voids are closed by restoring the rafts to unstressed conditions, mechanical recovery occurs, confirming the presence of concentration-dependent bond association that - combined with force-diminished dissociation - could further bolster network cohesion under certain stress states

Duration of adjuvant chemotherapy for stage III colon cancer

BACKGROUND Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures. METHODS We performed a prospective, preplanned, pooled analysis of six randomized, phase 3 trials that were conducted concurrently to evaluate the noninferiority of adjuvant therapy with either FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin) administered for 3 months, as compared with 6 months. The primary end point was the rate of disease-free survival at 3 years. Noninferiority of 3 months versus 6 months of therapy could be claimed if the upper limit of the two-sided 95% confidence interval of the hazard ratio did not exceed 1.12. RESULTS After 3263 events of disease recurrence or death had been reported in 12,834 patients, the noninferiority of 3 months of treatment versus 6 months was not confirmed in the overall study population (hazard ratio, 1.07; 95% confidence interval [CI], 1.00 to 1.15). Noninferiority of the shorter regimen was seen for CAPOX (hazard ratio, 0.95; 95% CI, 0.85 to 1.06) but not for FOLFOX (hazard ratio, 1.16; 95% CI, 1.06 to 1.26). In an exploratory analysis of the combined regimens, among the patients with T1, T2, or T3 and N1 cancers, 3 months of therapy was noninferior to 6 months, with a 3-year rate of disease-free survival of 83.1% and 83.3%, respectively (hazard ratio, 1.01; 95% CI, 0.90 to 1.12). Among patients with cancers that were classified as T4, N2, or both, the disease-free survival rate for a 6-month duration of therapy was superior to that for a 3-month duration (64.4% vs. 62.7%) for the combined treatments (hazard ratio, 1.12; 95% CI, 1.03 to 1.23; P=0.01 for superiority). CONCLUSIONS Among patients with stage III colon cancer receiving adjuvant therapy with FOLFOX or CAPOX, noninferiority of 3 months of therapy, as compared with 6 months, was not confirmed in the overall population. However, in patients treated with CAPOX, 3 months of therapy was as effective as 6 months, particularly in the lower-risk subgroup. (Funded by the National Cancer Institute and others.

Helical growth during the phototropic response, avoidance response, and in stiff mutants of Phycomyces blakesleeanus

The sporangiophores of Phycomyces blakesleeanus have been used as a model system to study sensory transduction, helical growth, and to establish global biophysical equations for expansive growth of walled cells. More recently, local statistical biophysical models of the cell wall are being constructed to better understand the molecular underpinnings of helical growth and its behavior during the many growth responses of the sporangiophores to sensory stimuli. Previous experimental and theoretical findings guide the development of these local models. Future development requires an investigation of explicit and implicit assumptions made in the prior research. Here, experiments are conducted to test three assumptions made in prior research, that (a) elongation rate, (b) rotation rate, and (c) helical growth steepness, R, of the sporangiophore remain constant during the phototropic response (bending toward unilateral light) and the avoidance response (bending away from solid barriers). The experimental results reveal that all three assumptions are incorrect for the phototropic response and probably incorrect for the avoidance response but the results are less conclusive. Generally, the experimental results indicate that the elongation and rotation rates increase during these responses, as does R, indicating that the helical growth steepness become flatter. The implications of these findings on prior research, the &ldquo;fibril reorientation and slippage&rdquo; hypothesis, global biophysical equations, and local statistical biophysical models are discussed. </div

Individual participant data network meta-analysis of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastroesophageal junction carcinoma

PURPOSEThe optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus (TE) or gastroesophageal junction (GEJ) remains a matter of debate. We performed an individual participant data (IPD) network meta-analysis (NMA) of randomized controlled trials (RCTs) to study the effect of chemotherapy or chemoradiotherapy, with a focus on tumor location and histology subgroups.PATIENTS AND METHODSAll, published or unpublished, RCTs closed to accrual before December 31, 2015 and having compared at least two of the following strategies were eligible: upfront surgery (S), chemotherapy followed by surgery (CS), and chemoradiotherapy followed by surgery (CRS). All analyses were conducted on IPD obtained from investigators. The primary end point was overall survival (OS). The IPD-NMA was analyzed by a one-step mixed-effect Cox model adjusted for age, sex, tumor location, and histology. The NMA was registered in PROSPERO (CRD42018107158).RESULTSIPD were obtained for 26 of 35 RCTs (4,985 of 5,807 patients) corresponding to 12 comparisons for CS-S, 12 for CRS-S, and four for CRS-CS. CS and CRS led to increased OS when compared with S with hazard ratio (HR) = 0.86 (0.75 to 0.99), P = .03 and HR = 0.77 (0.68 to 0.87), P P = .27 (consistency P = .26, heterogeneity P = .0038). For CS versus S, a larger effect on OS was observed for GEJ versus TE tumors (P = .036). For the CRS versus S and CRS versus CS, a larger effect on OS was observed for women (P = .003, .012, respectively).CONCLUSIONNeoadjuvant chemotherapy and chemoradiotherapy were consistently better than S alone across histology, but with some variation in the magnitude of treatment effect by sex for CRS and tumor location for CS. A strong OS difference between CS and CRS was not identified.Cellular mechanisms in basic and clinical gastroenterology and hepatolog

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations

BACKGROUND: The benefit of second-line chemotherapy (L2) over standard first-line (L1) gemcitabine plus cisplatin (GEMCIS) or oxaliplatin (GEMOX) chemotherapy in advanced biliary tract cancer (aBTC) is unclear. Our aim was to identify and validate prognostic factors for overall survival (OS) with L2 in aBTC to guide clinical decisions in this setting. METHODS: We performed a retrospective analysis of four prospective patient cohorts: a development cohort (28 French centres) and three validation cohorts from Italy, UK and France. All consecutive patients with aBTC receiving L2 after GEMCIS/GEMOX L1 between 2003 and 2016 were included. The association of clinicobiological data with OS was investigated in univariate and multivariate Cox analyses. A simple score was derived from the multivariate model. RESULTS: The development cohort included 405 patients treated with L1 GEMOX (91%) or GEMCIS. Of them, 55.3% were men, and median age was 64.8 years. Prior surgical resection was observed in 26.7%, and 94.8% had metastatic disease. Performance status (PS) was 0, 1 and 2 in 17.8%, 52.4% and 29.7%, respectively. Among 22 clinical parameters, eight were associated with OS in univariate analysis. In multivariate analysis, four were independent prognostic factors (p &lt; 0.05): PS, reason for L1 discontinuation, prior resection of primary tumour and peritoneal carcinomatosis. The model had the Harrell's concordance index of 0.655, a good calibration and was validated in the three external cohorts (N = 392). CONCLUSION: We validated previously reported predictive factors of OS with L2 and identified peritoneal carcinomatosis as a new pejorative factor in nearly 800 patients. Our model and score may be useful in daily practice and for future clinical trial design